[Tumor markers in the diagnosis and therapy of intestinal neoplasms].
Tumor-markers should only be used, if they could alter the management of the patient. Screening for hepatocellular cancer in patients with chronic liver disease and monitoring cancer therapy are established methods. In the future, benign and malignant diseases of the pancreas will become easier to differentiate by the determination of subgroups of Lewis A-antigens. During follow-up after curative surgery, markers are of limited value. Immunoscintigraphy is already in use, whereas therapy with monoclonal antibodies still remains investigational.
Gräter
H
H
Medizinische Klinik Esslingen, Fachbereich Gastroenterologie.
D000951:Antigens, Neoplasm / Q000302:isolation & purification; D014408:Biomarkers, Tumor / Q000302:isolation & purification*; D002272:Carcinoembryonic Antigen / Q000302:isolation & purification; D006801:Humans; D007414:Intestinal Neoplasms / Q000175:diagnosis* / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000276:immunology; D011379:Prognosis
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen
Tumormarker in Diagnostik und Therapie intestinaler Neoplasien.